Navigation Links
BioNeutral Group Receives $400,000 in Equity Financing
Date:12/27/2011

MORRISTOWN, N.J., Dec. 27, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology-based company, today announced that it has received $400,000 in connection with the Preferred Stock Purchase Agreement (the "Agreement") with Vinfluence Pty Ltd ("Vinfluence"), New South Wales, Australia.  Pursuant to the Agreement, BioNeutral Group, Inc. received $200,000 from the initial closing and a second funding of $200,000, both from the sale of Series C Convertible Preferred Stock.  As per the Agreement the company will receive monthly funding of $200,000 for each of the next three months, for a total funding of $1M.   Further details of the Preferred Stock Purchase Agreement can be found in our SEC filings.

Frank Battafarano, Chairman of the Board of BioNeutral Group, said, "We are pleased to have completed the closing with Vinfluence providing us with $400,000 in working capital.  Our recent financing has provided us with the opportunity to develop and further enhance our relationships with both new and existing key vendors and suppliers. We look forward to our relationship with Vinfluence in 2012 providing us with access to additional equity-based financing helping us to further commercialize our products."

About BioNeutral Group, Inc.

Headquartered in Morristown New Jersey with lab facilities at the New Jersey Institute of Technology in Newark New Jersey, BioNeutral Group, Inc. is a specialty technology-based life-science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores.  BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airbor
'/>"/>

SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services
2. BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review
3. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
4. BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
5. BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM)
6. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
7. BioNeutral Group to Receive Economic Development Incentives
8. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
9. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
10. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
11. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Propanc Health Group Corporation (OTCBB: ... on the development of cancer treatments for patients ... product includes PRP, a patented formulation consisting of ... well as the enzyme amylase designed to synergistically ... combination of anti-cancer agents working in combination with ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
(Date:4/22/2015)... April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced ... quarter 2015 on Thursday, May 7, 2015 after the ... webcast and conference call for 4.30 pm ET (1.30 ... Live audio of the conference call will be webcast ... members of the news media and the general public. ...
(Date:4/22/2015)... , April 22, 2015 Steep ... analytics, announced today that it has opened an ... continued growth and expansion.  The common stock investment ... Section 506(c), a law intended to encourage funding ... Prior to 506(c), small businesses largely relied on ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Amex: NBS ) ("NeoStem" or the "Company"), an ... today announced that the Company and its wholly-owned subsidiary, Progenitor ... conferences: the 2011 World Stem Cell Summit, the AABB Annual ... 2011 World Stem Cell Summit – ...
... Oct. 4, 2011 Exosome Diagnostics, a leading ... in personalized medicine, today announced the appointment of ... Donovan, M.D., Ph.D., as chief medical officer, and ...  Raphael Bueno, M.D., associate chief of cardiothoracic surgery ...
... have discovered two early-stage phases of carbon nanotube growth ... tangle of tube growth that ultimately yields to orderly ... in the latest edition of the journal Nanotechnology ... Professor of Physics Zhifeng Ren and researcher Dr. Hengzhi ...
Cached Biology Technology:NeoStem Announces Participation in Multiple October Conferences 2NeoStem Announces Participation in Multiple October Conferences 3NeoStem Announces Participation in Multiple October Conferences 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Boston College Researchers discover 2 early stages of carbon nanotube growth 2
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Cancer Cell describes a small molecule inhibitor of polo-like kinase1 ... cancer therapy. The compound, ON01910, is a potent inhibitor of ... toxicity. The results of this study have led to clinical ... Plk1 is a molecule that plays a key role in ...
... proteins called phosphatases play a key role in the ... fruit flies and mice by researchers at the University ... collaboration with scientists at the Salk Institute, La Jolla, ... stem cells and for silencing expression of neuronal genes ...
... toward understanding the regulation of blood stem cells and ... research study published in the February issue of Developmental ... to examine the role of a key gene known ... from this research will be useful for future studies ...
Cached Biology News:New drug shows promise as powerful anticancer agent 2New insight into regulation of blood stem cells 2
BD BioCoat Collagen IV 150 mm Culture Dishes...
Polymerase (RNA) II (DNA directed) polypeptide L...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
Biology Products: